Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

Explore Allogene's innovative CAR-T therapies targeting cancer & autoimmune diseases. ASCO updates on ALLO-316 could validate ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta ...

Hair loss can be a frustrating experience, whether it’s thinning, receding, or shedding in patches. It affects millions of ...

Citizens' groups converged on the Capitol Tuesday to demand that Gov. Evers fight harder for progressive budget priorities ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Zai Lab accelerates innovative drug launches in China through partnerships and expertise, targeting $1.5-$2B revenue by 2028.

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic ...

The Australian man accused of smuggling more than $1 million worth of cocaine into Bali says he didn't know what he was picking up.

A group of dedicated social workers are helping stamp out anti-social behaviour and support vulnerable Victorians.